Denosumab for the treatment of osteoporosis
Denosumab for the treatment of osteoporosis
复制标题
DOI：
10.31491/apt.2020.09.034
复制
发表时间：
2020-09
期刊：
影响因子：
--
通讯作者：
S. Teo
中科院分区：
文献类型：
--
作者：
S. Teo
Denosumab是一种与核因子受体激活剂κB配体结合的单抗，可降低破骨细胞活性和骨转换。在骨质疏松症患者中每6个月使用Denosumab进行的骨折复位评估(FREE)试验显示，使用Denosumab增加骨密度(BMD)可显著降低骨折的相对风险。在男性骨质疏松症患者(ADAMO)中进行的地诺舒单抗与安慰剂的对比试验表明，在改善男性骨密度和减少骨转换方面，地诺单抗具有类似的效果。然而，人们担心停止使用Denosumab会增加骨折的风险。在进一步的证据可用之前，建议使用双膦酸类药物通过停用地诺单抗来降低这种风险。关键词：Denosumab，骨折，骨质疏松
Denosumab is a monoclonal antibody which binds to the receptor activator of nuclear factor- κB ligand (RANKL), reducing osteoclastic activity and bone turnover. The Fracture REduction Evaulation of Denosumab in Osteoporosis every 6 Months (FREEDOM) trial showed a significant reduction in relative risk of fractures with increased bone mineral density (BMD) with denosumab. A trial of DenosumAb versus placebo in Males with Osteoporosis (ADAMO) demonstrated the similar effect of denosumab for improving BMD and reducing bone turnover in men. However, concerns were identified regarding increased risk of fractures with denosumab cessation. Until further evidence is available, bisphosphonate treatment is recommended to attenuate this risk with denosumab discontinuation. Keywords: Denosumab, fracture, osteoporosis